GlassScriptPhysician profile
Emily Watson
NPI 1407435415
$714.68
in general payments reported to CMS, 2019-2025
13 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $149 · 2024: $440 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $153.32 | 2023-2024 | Epidiolex |
| Takeda Pharmaceuticals U.S.A., INC. | $107.11 | 2023-2024 | Hyqvia |
| Emd Serono, INC. | $103.36 | 2023-2024 | Mavenclad |
| Sk Life Science, INC. | $59.56 | 2024 | |
| Alexion Pharmaceuticals, INC. | $58.23 | 2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $49.15 | 2024-2025 | Andexxa, Wainua |
| Averitas Pharma INC. | $45.26 | 2023-2024 | Qutenza |
| Alnylam Pharmaceuticals INC. | $41.45 | 2025 | Onpattro |
| Genentech USA, INC. | $28.64 | 2025 | Ocrevus Zunovo |
| Lilly USA, LLC | $19.08 | 2025 | Amyvid, Kisunla |
| Amylyx Pharmaceuticals, INC. | $16.90 | 2024 | Relyvrio |
| Neurelis, INC. | $16.48 | 2024 | Valtoco |
| Tg Therapeutics, INC. | $16.14 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.